Short description:
Cancer Therapeutics, Immuno-Oncology
Drug notes:
TNG462 Clin1/Clin2 oncology; TNG260 Clin1/Clin2 oncology; TNG348 Clin0 cancers
Long description:
Tango Therapeutics is using the principle of synthetic lethality to develop medicines for cancer patients. Synthetic lethality describes a situation where loss of two targets results in cell death, while loss of either one alone does not. Since some tumors already possess target loss, Tango is using their CRISPR-based functional genomics target discovery platform and analytic pipeline to identify novel synthetic lethal targets that can selectively kill tumor cells. Tango is applying this approach in two core areas: [1] tumor suppressor gene loss and [2] immune evasion. Once targets are identified, Tango screens for drugs that have therapeutic potential. Tango’s lead candidate, TNG908, is being evaluated in clinical trials for MTAP-deleted tumors.
Jobs:
Associate Scientist I/II, Immunology Boston, MA|4 days ago
Director/Senior Director, Clinical Pharmacology Boston, MA|17 days ago
Research Informatics Summer Intern 2024 Boston, MA|29 days ago
Manager, Biosamples Boston, MA|60 days ago
Staff Accountant Boston, MA|85 days ago
Director, Clinical Operations Boston, MA|100+ days ago
Clinical Trial Manager Boston, MA|100+ days ago
Director, GXP Quality Boston, MA|100+ days ago